MicroRNA research project receives grant  

2006.01.12
The Danish High Technology Fund has granted EUR 1.3 m for a research project in microRNA which is being conducted in collaboration between University of Copenhagen and Santaris Pharma

The Danish High Technology Fund has granted EUR 1.3 m (USD 1.6 m) for a research project in microRNA (miRNA) which is being conducted in collaboration between the Department for Medical Biochemistry and Genetics at the University of Copenhagen and Santaris Pharma, a biopharmaceutical company based in Hørsholm Science Park, north of Copenhagen.

The project aims to map miRNA genes associated with oncogenesis, and further to use this knowledge to develop new pharmaceutical substances for the treatment of cancer based on locked nucleic acids (LNAs).

Researchers have found hundreds of miRNA genes in humans, which control processes such as cell growth, differentiation and development. Recently a connection between miRNA and cancer was discovered which showed that changed miRNA patterns can cause cancer. The news was reported by BiotechDenmark.

Santaris Pharma is a result of a merger between Pantheco and Cureon in 2003. The company focuses on developing next generation of RNA-silencing drugs based on its proprietary LNA technology for the treatment of cancer and metabolic disorders.

Link > Santaris Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×